GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Valuation Rank

4SC AG (FRA:VSC) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is 4SC AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

4SC AG Valuation Rank Related Terms

Thank you for viewing the detailed overview of 4SC AG's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

4SC AG (FRA:VSC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Valuation Rank
Comparable Companies
XTER:MDG1 XTER:HPHA XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY TECH UTHR
Traded in Other Exchanges
VSC:Germany
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
Website
https://www.4sc.com
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.